J. Ferlay, Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012: Globocan 2012, International Journal of Cancer, vol.136, pp.359-386, 2015.

K. A. Olaussen and S. Postel-vinay, Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape, Annals of Oncology, vol.27, 2004.

P. Tomasini, F. Barlesi, C. Mascaux, and L. Greillier, Pemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomes, Therapeutic Advances in Medical Oncology, vol.8, pp.198-208, 2016.

M. A. Socinski, T. E. Stinchcombe, and D. N. Hayes, The evolving role of pemetrexed (Alimta) in lung cancer, Seminars in Oncology, vol.32, pp.16-22, 2005.

A. A. Adjei, Pharmacology and Mechanism of Action of Pemetrexed, Clinical Lung Cancer, vol.5, pp.51-55, 2004.

J. R. Molina and A. A. Adjei, The Role of Pemetrexed (Alimta ® , LY231514) in Lung Cancer Therapy, Clinical Lung Cancer, vol.5, pp.21-27, 2003.

S. Roy and G. Trinchieri, Microbiota: a key orchestrator of cancer therapy, Nature Reviews Cancer, vol.17, pp.271-285, 2017.

W. S. Garrett, Cancer and the microbiota, Science, vol.348, pp.80-86, 2015.

S. Viaud, Gut microbiome and anticancer immune response: really hot Sh*t!, Cell Death and Differentiation, vol.22, pp.199-214, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01204458

B. D. Wallace, Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme, Science, vol.330, pp.831-835, 2010.

J. Guillen, FELASA Guidelines and Recommendations, Journal of the American Association for Laboratory Animal Science, vol.51, pp.311-321, 2012.

M. Ilie, Setting up a wide panel of patient-derived tumor xenografts of non-small cell lung cancer by improving the preanalytical steps, Cancer Medicine, vol.4, pp.201-211, 2015.

A. Klindworth, Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencingbased diversity studies, Nucleic acids research, vol.41, p.1, 2013.

, Scientific RepoRtS |, vol.10, p.9094, 2020.

P. D. Schloss, Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities, Applied and environmental microbiology, vol.75, pp.7537-7578, 2009.

. R-core-team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, 2015.

P. Fança-berthon, C. Hoebler, E. Mouzet, A. David, and C. Michel, Intrauterine growth restriction not only modifies the cecocolonic microbiota in neonatal rats but also affects its activity in young adult rats, J. Pediatr. Gastroenterol. Nutr, vol.51, pp.402-413, 2010.

P. D. Cani, Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice, Diabetes, vol.57, pp.1470-1481, 2008.
URL : https://hal.archives-ouvertes.fr/inserm-00410066

P. Venegas and D. , Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for, Inflammatory Bowel Diseases. Front. Immunol, vol.10, 2019.

C. Duvallet, S. M. Gibbons, T. Gurry, R. A. Irizarry, and E. J. Alm, Meta-analysis of gut microbiome studies identifies disease-specific and shared responses, Nat Commun, vol.8, p.1784, 2017.

H. M. Hamer, Review article: the role of butyrate on colonic function: REVIEW: ROLE OF BUTYRATE ON COLONIC FUNCTION, Alimentary Pharmacology & Therapeutics, vol.27, pp.104-119, 2007.

H. Zheng, Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine, Frontiers in Microbiology, vol.8, 2017.

T. Wang, Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers, ISME J, vol.6, pp.320-329, 2012.

H. Tilg, T. E. Adolph, R. R. Gerner, and A. R. Moschen, The Intestinal Microbiota in Colorectal Cancer, Cancer Cell, vol.33, pp.954-964, 2018.

R. Sinha, Fecal Microbiota, Fecal Metabolome, and Colorectal Cancer Interrelations, PLoS ONE, vol.11, p.152126, 2016.

H. Nagao-kitamoto and N. Kamada, Host-microbial Cross-talk in Inflammatory Bowel Disease, Immune Netw, vol.17, pp.1-12, 2017.

A. Salonen, W. M. De-vos, and A. Palva, Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives, Microbiology, vol.156, pp.3205-3215, 2010.

A. Chávez-carbajal, Gut Microbiota and Predicted Metabolic Pathways in a Sample of Mexican Women Affected by Obesity and Obesity Plus Metabolic Syndrome, Int J Mol Sci, vol.20, 2019.

K. Kameyama and K. Itoh, Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice, Microbes Environ, vol.29, pp.427-430, 2014.

S. Li, Lachnospiraceae shift in the microbial community of mice faecal sample effects on water immersion restraint stress, AMB Express, vol.7, 2017.

H. Zeng, S. L. Ishaq, F. Zhao, and A. G. Wright, Colonic inflammation accompanies an increase of ?-catenin signaling and Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice, The Journal of Nutritional Biochemistry, vol.35, pp.30-36, 2016.

C. Niyikiza, Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy, Mol. Cancer Ther, vol.1, pp.545-552, 2002.

P. M. Wilson, P. V. Danenberg, P. G. Johnston, H. Lenz, and R. D. Ladner, Standing the test of time: targeting thymidylate biosynthesis in cancer therapy, Nature Reviews Clinical Oncology, vol.11, pp.282-298, 2014.

E. Nistal, N. Fernández-fernández, S. Vivas, and J. L. Olcoz, Factors Determining Colorectal Cancer: The Role of the Intestinal Microbiota, Frontiers in Oncology, vol.5, 2015.

N. Shin, T. W. Whon, and J. Bae, Proteobacteria: microbial signature of dysbiosis in gut microbiota, Trends in Biotechnology, vol.33, pp.496-503, 2015.

E. Montassier, 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation, Microb. Ecol, vol.67, pp.690-699, 2014.

I. Mukhopadhya, R. Hansen, E. M. El-omar, and G. L. Hold, IBD-what role do Proteobacteria play?, Nature Reviews Gastroenterology & Hepatology, vol.9, pp.219-230, 2012.

E. R. Hughes, Microbial Respiration and Formate Oxidation as Metabolic Signatures of Inflammation-Associated Dysbiosis, Cell Host & Microbe, vol.21, pp.208-219, 2017.

R. J. Rigby, Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis, Gut Microbes, vol.7, pp.414-423, 2016.

M. Derrien, Mucin-bacterial interactions in the human oral cavity and digestive tract, Gut Microbes, vol.1, pp.254-268, 2010.

J. Sun, Therapeutic Potential to Modify the Mucus Barrier in Inflammatory Bowel Disease, Nutrients, vol.8, p.44, 2016.

M. F. De-la-cochetiere, Resilience of the Dominant Human Fecal Microbiota upon Short-Course Antibiotic Challenge, Journal of Clinical Microbiology, vol.43, pp.5588-5592, 2005.
URL : https://hal.archives-ouvertes.fr/hal-02682740

M. Van-de-guchte, H. M. Blottière, and J. Doré, Humans as holobionts: implications for prevention and therapy, vol.6, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02625522